Targeted Therapy of Ewing's Sarcoma

Table 3

Uncommon (<10%) Grade 3 and 4 toxicities of antiinsulin-like growth factor 1 receptor (IGF1R) antibodies.

Anti-IGF1R antibody	Grade 3 or 4 toxicity	Reference
R1507	Phase I: lymphopenia, thrombocytopenia, adrenal hemorrhage, hyperglycemia, DVT/PE, CVA;phase II: thrombocytopenia, anemia, pain, hyponatremia, hyperglycemia	[9, 26]
CP-751,871; (figitumumab)	Fatigue, pain, hyperglycemia, increased LFTs, proteinuria; with mTOR RAD001 (everolimus): nausea, fatigue, diarrhea, hypophosphatemia, mucositis	[7, 42]
AMG-479	Phase I: thrombocytopenia, hyperglycemia; phase II: thrombocytopenia, anemia, pain, dyspnea, nausea/vomiting, hyperglycemia	[8, 27]
SCH-717454; (robatumumab)	Constipation, hyperglycemia, back pain	[24]
IMC-A12; (cixutumumab)	With mTOR inhibitor (temsirolimus): hypercholesterolemia, hypertriglyceridemia, hyperglycemia, mucositis (all of these events can be ascribed at least in part to temsirolimus)	[28]
MK-0646	Thrombocytopenia, skin rash, hyperglycemia, fatigue, GI bleeding, elevated LFTs, respiratory problems	[29]

DVT: deep venous thrombosis; PE: pulmonary embolism; CVA: cerebrovascular accident; LFT: liver function test; mTOR: mammalian target of rapamycin; GI: gastrointestinal.
Note: Grade 3 or 4 toxicities have been seen in <10% of patients. These antibodies have generally been very well tolerated with few side effects compared to standard EWS chemotherapy.